CIITA and Parkinson disease: The level of MHCII on antigen-presenting cells is controlled by the class II transactivator (CIITA, also known as MHC2TA) and in vivo silencing of Ciita using shRNA has been shown to prevent neurodegeneration in a nigral α-Syn overexpression model of PD in mice [13].